2026 Interim report
Filed with HKEX · Stock code 6996 · · 67 pages · English
Summary by 6ix AI
The report highlights a significant increase in revenue compared to the same period last year, primarily driven by licensing and collaboration agreements. Additionally, the company reported a turnaround from a loss to a profit during this reporting period, reflecting improved operational efficiency and increased drug development expenses. The report also outlines advancements in Antengene's product pipeline and collaborations with other biopharmaceutical companies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Antengene Corporation Limited on 6ix
Earlier from Antengene
- Next Day Disclosure Return
- Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
- Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
- Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
- Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
Later from Antengene
- Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
Follow Antengene into a list and get an email when it puts out news.
Follow Antengene